

## EQA round: GP2/24 - Detection of Monoclonal Components

Deadline: 20.9.2024

Setup: groups - R (manufacturer of kit)

AV = assigned value	N <sub>tot</sub> = total number of the results	N <sub>eva</sub> = number of the results assessed
CVP = consensus of all participants	N <sub>rel</sub> = relative number of the results	N <sub>suc</sub> = number of successful results
>>> ... expected result		S <sub>rel</sub> = relative success
> ... acceptable result		
± ... result not assessed		

Test Sample Group	Frequency of the results				Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]

## Set 1 (plasma)

(246) <b>Gammopathies (typisation) (plasma)</b>		96			96	91	95
<b>Sample A1</b>		96			96	94	98
(12) Beckman Coulter	CVP >>>	1	1	IgG-lambda			
(34) Sebia		1	1	IgM-kappa			
	CVP >>>	65	68	IgG-lambda			
(100) Helena	CVP >>>	1	1	IgG-lambda			
(213) Interlab Srl	CVP >>>	27	28	IgG-lambda			
		1	1	IgM-lambda			
<b>Sample B1</b>		96			96	91	95
(12) Beckman Coulter	CVP >>>	1	1	IgM-kappa			
(34) Sebia	CVP >>>	60	63	IgM-kappa			
	>	2	2,1	IgM-kappa; kappa-free			
		1	1	IgM-kappa; IgA-lambda			
		1	1	IgM-kappa; lambda-free			
		1	1	IgG-lambda			
		1	1	IgM-lambda			
(100) Helena	CVP >>>	1	1	IgM-kappa			
(213) Interlab Srl		1	1	IgG-kappa			
	CVP >>>	27	28	IgM-kappa			

## Set 2 (urine)

(540) <b>Gammopathies (typisation) (urine)</b>		71			71	57	80
<b>Sample A2</b>		71			71	61	86
(0) not specified	CVP >>>	3	4,2	kappa-free			
(34) Sebia		1	1,4	kappa			
	CVP >>>	32	45	kappa-free			
		3	4,2	kappa-free; IgA-kappa			
	>	12	17	kappa-free; kappa			
		1	1,4	kappa-free; kappa; IgA-kappa			
		1	1,4	kappa-free; kappa; lambda			
		1	1,4	kappa-free; lambda-free			
(91) Binding Site	CVP >>>	1	1,4	kappa-free			
(213) Interlab Srl		2	2,8	kappa			
	CVP >>>	5	7	kappa-free			
	>	8	11	kappa-free; kappa			
		1	1,4	kappa-free; lambda-free			
<b>Sample B2</b>		71			71	65	92
(0) not specified	CVP >>>	2	2,8	kappa-free			
	>	1	1,4	kappa-free; kappa			
(34) Sebia	CVP >>>	19	27	kappa-free			
	>	17	24	kappa-free; IgA-kappa			
	>	12	17	kappa-free; kappa			
		2	2,8	kappa-free; kappa; IgA-kappa			
		1	1,4	lambda; lambda-free			
(91) Binding Site	CVP >>>	1	1,4	kappa-free			
(213) Interlab Srl		1	1,4	kappa			
	CVP >>>	4	5,6	kappa-free			
	>	3	4,2	kappa-free; IgA-kappa			
		1	1,4	kappa-free; IgM-kappa			
	>	6	8,5	kappa-free; kappa			
		1	1,4	kappa-free; kappa; IgA-kappa			